Stock Groups

Sweden to give 12-15 year olds Pfizer vaccine, rejects Moderna By Reuters

by Mike Robinson

[ad_1]

© Reuters. Pictured at Malmo’s Skane University Hospital, Sweden on February 17, 2021, are used vials from the Pfizer BioNTech, Moderna, and AstraZeneca coronavirus diseases (COVID-19), vaccines. TT News Agency/Johan Nilsson via REUTERS ATTENTION EDI

STOCKHOLM, (Reuters) – The Swedish Public Health Agency recommended Monday that children aged 12-15 years old use the Pfizer BioNTech Comirnaty vaccination against COVID-19. It is not preferred over rivals Moderna Spikevax.

Comirnaty was approved by the European Medicines Agency in May. Spikevax, which is for children older than 12, received approval in July.

Anders Tegnell (head of the department, state epidemiologist, Health Agency) stated that “All things considered, there is reason to select the vaccine we are most familiar with and have the best evidence for when it comes time to immunizing children aged 12-15 years.”

Agency claimed that there were more details about Comirnaty’s effect on children.

Spikevax was not recommended to the youngest generation of Swedish citizens, according to a statement by the Agency.

Agency stated in September that all children over 12 would receive a COVID shot starting October 11.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]